The annual Northwest Rheumatism Society is meeting from April 27 through April 29, 2017. It is an opportunity for rheumatologists and rheumatology trainees from the Pacific Northwest and Western Canada to come together to rekindle fellowship and receive an update on the latest research, diagnosis and treatment paradigms for rheumatologic disease.
Rotating among Seattle, Portland, and Vancouver, BC, regional experts and invited rheumatology luminaries from outside the US and Canada deliver state-of-the-art review lectures, punctuated by panel-audience discussion and debate.
This year in Seattle, the introductory keynote lecture at the Thursday evening dinner will be presented by Brian Arbogast, Director of Global Water and Hygiene for the Bill and Melinda Gates Foundation, who is slated to give an entertaining and eye opening look at some of the incoming issues that we as a global community and as citizens face regarding clean water and waste management, i.e. “T2T” (No, not “Treat to Target” but rather “Toilet to Tap”) – spouses/partners are welcome.
The concluding keynote will be by visiting professor Ron van Vollenhoven, Chair of Coordinated Rheumatology Divisions in Amsterdam: “Year in Review: RA and Lupus.”
There will be a pre-meeting ultrasound workshop, beginning at 1PM on Thursday, April 27, including a focus on vascular imaging (screening for GCA) with visiting professor from Norway, Andreas Diamantopoulos, who will also present at the main meeting.
By the end of the conference, participants will be able to:
- Identify and describe the pros and cons of the use of MTX as monotherapy versus in combination with biologics in various disease states: rheumatoid arthritis, psoriatic arthritis and spondyloarthritis.
- Develop a deeper understanding and describe new concepts in spondyloarthritis patholophysiology and clinical presentation.
- Describe current knowledge and issues in best practices for transitioning pediatric to adult rheumatology care.
- Apply recent advances and new evidence into practice to optimize treatment of patients with rheumatic diseases.
Abbvie, Altus Health System, Amgen, Arthritis Foundation, Celgene, Crescendo Bioscience, Eli Lilly, FreemanXP, Frictionless Solutions, Genentech, GSK, Intrafusion, Ironwood Pharmaceuticals, Janssen, Mallinckrodt, Medac, Novartis, Pfizer, Regeneron, Women in Rheumatology, Young Rheumatologist
For More Information
For more information, please contact Marita Keppel at email@example.com or 503-709-2280.